Overview
- A federal securities class action, captioned Mazzarino v. ADMA Biologics, No. 26‑cv‑06918, has been filed in the U.S. District Court for the District of New Jersey on behalf of buyers of ADMA stock during the named class period.
- The complaint alleges ADMA hid a related‑party distributor, used channel stuffing to inflate reported revenue, and lacked adequate internal controls, and it asserts claims under the Securities Exchange Act.
- The lawsuit traces the market trigger to a March 24, 2026 short‑seller report by Culper Research that accused ADMA of channel stuffing and an undisclosed related party and that the complaint says caused the stock to fall more than 16%.
- Since the filing, several plaintiff‑side law firms have issued notices asking investors to join the case or to move for lead‑plaintiff appointment, and firms stress the procedural deadline to seek lead status is August 10, 2026.
- Next steps include competing lead‑plaintiff motions, appointment of counsel, and discovery and motion practice to test the allegations; the claims remain unproven and any recovery would come through litigation or settlement.